MedTrace Logo

Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride

NCT01802866 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 508

Last updated 2017-07-02

No results posted yet for this study

Summary

The purpose of this study is to determine if emixustat hydrochloride (ACU-4429) reduces the rate of progression of geographic atrophy compared to placebo in subjects with dry age-related macular degeneration.

Conditions

Interventions

DRUG

ACU-4429

Take orally once daily for 24 months

DRUG

Placebo

Take orally once daily for 24 months

Sponsors & Collaborators

  • Otsuka Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Kubota Vision Inc.

    lead INDUSTRY

Principal Investigators

  • Acucela Medical Monitor · Kubota Vision Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2016-04-30
Completion
2016-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01802866 on ClinicalTrials.gov